Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck KGaA aimed at discovering small-molecule RNA-targeted drugs that could be worth more than $2 billion.
A little-known tissue composed of a cluster of immune cells could offer novel insights into the development of neurological disorders. Meninges' immune system changes with age and neurodegeneration. Are they protecting the brain or fueling disease?
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Beam, Everest, Halda, Sanofi, Shilpa.
Biopharma happenings, including deals and partnerships, and other news in brief: Arrowhead, Basilea, Norgine, Sarepta, Schrödinger, Theravia, Vedanta, Venatorx.
RSS
